Powered by: Motilal Oswal
17/12/2021 12:58:15 PM | Source: Angel One Ltd
Quote on Supriya Lifescience Limited IPO subscribed 3.07 times on Day -2 By Yash Gupta, Angel One Ltd
News By Tags | #6943 #607 #442 #7106 #6174
Quote on Supriya Lifescience Limited IPO subscribed 3.07 times on Day -2 By Yash Gupta, Angel One Ltd

Below is quote on Supriya Lifescience Limited IPO subscribed 3.07 times on Day -2 By Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd   

Supriya Lifescience Limited IPO received good response from retail investors, overall IPO subscribed 3.07 times and retail portion subscribed more than 15 times. Non institutional investors (NII) and Qualified institutional buyer (QIB) have not shown much response as of now, we have seen in earlier IPOs that both investors apply on the 3rd day or the last day of the IPO. 

We have a Subscribe rating on Supriya Lifescience Limited IPO, IPO has been priced at an EV/EBITDA of 11.2 times and price to earnings of 16.2 times at the upper price band of the IPO. . Supriya Lifescience Limited focuses on research & development and having a diversified niche product portfolio of API’s. Companies 77.5% of revenue comes from the Export market, companies’ key markets are USA, Europe, China and India. We believe that the company's new manufacturing unit and product launch will be growth drivers for the company in future.

 

Above views are of the author and not of the website kindly read disclaimer

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here